Thyroid eye disease is an auto-immune mediated orbitopathy which can cause dysthyroid compressive optic neuropathy. Traditional management of active thyroid eye disease includes temporizing high-dose steroids, orbital radiation and surgical decompression, which each possess significant limitations and/or side effects. Teprotumumab is an IGF-IR inhibitor recently FDA-approved for active thyroid eye disease. The authors report reversal of bilateral dysthyroid compressive optic neuropathy managed medically utilizing teprotumumab.
BahnRS.Graves’ ophthalmopathy. N Engl J Med2010; 362: 726–738.
2.
BlandfordADZhangDChunduryRV, et al. Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol2017; 12: 111–121.
3.
DouglasRSKahalyGJPatelA, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med2020; 382: 341–352.
4.
MarkhamA.Teprotumumab: First approval. Drugs2020; 80: 509–512.
5.
SearsCMAzadADDosiouC, et al. Teprotumumab for dysthyroid optic neuropathy: Early response to therapy. Ophthalmic Plast Reconstr Surg. Epub ahead of print September 2020. DOI: 10.1097/IOP.0000000000001831.
6.
SmithTJ.Teprotumumab treatment for thyroid-associated ophthalmopathy. Eur Thyroid J2020; 9: 31–39.
